Why the study?
Do natriuretic peptides improve outcomes and reduce mortality in acute renal failure?
Population
Acute renal failure (ARF)
Design
Review
Follow-up
6 days (for mortality finding)
Authors
Loading...
Should not yet change ARF practice; leaves open confirmation of vessel dilator benefit in randomized trials.
Do natriuretic peptides improve outcomes and reduce mortality in acute renal failure?
Natriuretic peptides, particularly vessel dilator, show significant therapeutic potential in ameliorating acute tubular necrosis and reducing mortality in acute renal failure.
David L. Vesely (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: